Evidence map›Paper›PMID 28814540›Full record

Observational studyPediatrics2017

Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment.

Walter E Kaufmann, Sharon A Kidd, Howard F Andrews, Dejan B Budimirovic, Amy Esler, Barbara Haas-Givler, Tracy Stackhouse, Catharine Riley, Georgina Peacock, Stephanie L Sherman and 2 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 184 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
184citing papers in PubMed, 7 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

184 citing papers in PubMed, 7 syntheses or guidelines pooled it, 271 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Effects of AFQ056 on language learning in fragile X syndrome.The Journal of clinical investigation · 2023
    Trial
  10. Lasting effects of early-life oxytocin treatment on LTP and episodic memory in a mouse model of Fragile X syndrome.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  11. Article
  12. Article
  13. Profile of Behavioral Comorbidities in Children With Fragile X Syndrome.Journal of autism and developmental disorders · 2026
    Article
  14. Article
  15. Article
  16. Review
  17. Aberrant Neural Entrainment to Word-Level Speech Patterns in Fragile X Syndrome: Evidence for a Statistical Learning Deficit.Autism research : official journal of the International Society for Autism Research · 2026
    Article
  18. Article
  19. Review
  20. Article

124 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 12 institutions in 1 country.

Walter E KaufmannDepartment of Neurology, Boston Children's Hospital, Boston, Massachusetts; wkaufmann@ggc.org.
Sharon A KiddNational Fragile X Foundation, Washington, District of Columbia.
Howard F AndrewsDepartment of Biostatistics, Columbia University Mailman School of Public Health, New York, New York.
Dejan B BudimirovicKennedy Krieger Institute, Baltimore, Maryland.
Amy EslerUniversity of Minnesota, Minneapolis, Minnesota.
Barbara Haas-GivlerGeisinger Health System, Lewisburg, Pennsylvania.
Tracy StackhouseDevelopmental FX, Denver, Colorado.
Catharine RileyNational Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia.
Georgina PeacockNational Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia.
Stephanie L ShermanDepartment of Human Genetics, Emory University School of Medicine, Atlanta, Georgia.
W Ted BrownNew York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York; and.
Elizabeth Berry-KravisDepartments of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Center, Chicago, Illinois.
Boston Children's Hospital · USCenters for Disease Control and Prevention · USColumbia University · USEmory University · USFX Palo Alto Laboratory · USGeisinger Health System · USKennedy Krieger Institute · USNational Center on Birth Defects and Developmental Disabilities · USNational Fragile X Foundation · USNew York State Office for People With Developmental Disabilities · USRush University Medical Center · USUniversity of Minnesota · US

Funding

Cooperative Agreement for a Nat'l Research & Training Org for People with DevelopU01DD000231 · DD · ASSN OF UNIVERSITY CENTERS/ DISABILITIES · PI JESIEN, GEORGE S. · 2007 to 2012
$16.8M
Mouse Neurodevelopmental Behavior CoreU54HD090255 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI POMEROY, SCOTT LOREN · 2016 to 2020
$5.2M
Pilot Longitudinal Data Collection to Inform Public Health_Fragile X SyndromeU19DD000753 · DD · INSTITUTE FOR BASIC RES IN DEV DISABIL · PI BROWN, WILLIAM TED · 2011 to 2014
$2.3M
Using Longitudinal Data to Characterize the Natural History of Fragile X Syndrome--Component AU01DD001189 · DD · INSTITUTE FOR BASIC RES IN DEV DISABIL · PI VELINOV, MILEN T · 2015 to 2019
$1.7M
Intramural CDC HHS CC999999NCBDD CDC HHS U01 DD000231NCBDD CDC HHS U01 DD001189NCBDD CDC HHS U19 DD000753NICHD NIH HHS U54 HD090255
6 · The paper itself

Abstract

BACKGROUND AND

objectiveIndividuals with fragile X syndrome (FXS) are frequently codiagnosed with autism spectrum disorder (ASD). Most of our current knowledge about ASD in FXS comes from family surveys and small studies. The objective of this study was to examine the impact of the ASD diagnosis in a large clinic-based FXS population to better inform the care of people with FXS.

methodsThe study employed a data set populated by data from individuals with FXS seen at specialty clinics across the country. The data were collected by clinicians at the patient visit and by parent report for nonclinical and behavioral outcomes from September 7, 2012 through August 31, 2014. Data analyses were performed by using χ

resultsHalf of the males and nearly 20% of females met

conclusionsThese findings confirm among individuals with FXS an association of an ASD diagnosis with important cooccurring conditions and identify gaps between expected and observed treatments among individuals with FXS+ASD.

Indexed as

AdolescentAdrenergic alpha-AgonistsAdultAntipsychotic AgentsApplied Behavior AnalysisAutism Spectrum DisorderChildChild Behavior DisordersChild, PreschoolCombined Modality TherapyComorbidityDiagnostic and Statistical Manual of Mental DisordersFemaleFragile X SyndromeHumansInfantAdrenergic alpha-AgonistsAntipsychotic Agents

Identifiers

PMID28814540
PMCPMC5619699
OpenAlexW2620588197

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.